Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Liabilities and Shareholders Equity (2021 - 2025)

Lucid Diagnostics (LUCD) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $53.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity rose 135.41% year-over-year to $53.2 million, compared with a TTM value of $155.4 million through Sep 2025, up 33.91%, and an annual FY2024 reading of $30.7 million, up 12.63% over the prior year.
  • Liabilities and Shareholders Equity was $53.2 million for Q3 2025 at Lucid Diagnostics, up from $38.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $62.1 million in Q1 2022 and bottomed at $3.3 million in Q3 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $37.5 million, with a median of $34.1 million recorded in 2024.
  • Peak annual rise in Liabilities and Shareholders Equity hit 1064.21% in 2022, while the deepest fall reached 44.9% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $59.0 million in 2021, then plummeted by 44.9% to $32.5 million in 2022, then dropped by 16.12% to $27.3 million in 2023, then grew by 12.63% to $30.7 million in 2024, then skyrocketed by 73.2% to $53.2 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for LUCD at $53.2 million in Q3 2025, $38.7 million in Q2 2025, and $32.8 million in Q1 2025.